Dianthus | Hit Screening
-
Read
Because you demand fast, non-stop, highly sensitive hit screening.
-
2:55WatchGet fast, non-stop, highly sensitive hit screening with Dianthus.
Dianthus removes the complexity of binding interaction measurements for drug discovery screening. Find hits for any target type in any buffer or bioliquid, measure the tightest interactions down to pi
-
Read
Going small to win big: Fragment-based screening in drug discovery
-
Have a question about Dianthus?
Contact Specialist -
ReadThe NanoTemper Story – Chapter 5: The Dianthus
Almost as soon as the Monolith launched, the handful of people that made up NanoTemper in those early days huddled around, brainstorming how to translate the technology into a well-based assay....
-
17:10WatchTackle the high-hanging fruits in challenging drug discovery pipelines
There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t
-
Read
Fast molecular interaction screening of epigenetic gene regulator G9a with fragments from a large chemical space
-
Read
Easily characterize the molecular mechanisms of neurodegenerative diseases
-
Read
Fast-track your hit screening assay development with the Buffer Exploration Kit
-
17:07WatchTackle small molecule drug discovery screening challenges with Dianthus
A big hurdle in small molecule drug discovery screening is confidently identifying positive hits in a timely manner. Screening fragment libraries is challenging with current methodologies that are eit
-
Read3 big takeaways from SLAS on the future of automation and screening
5,200 researchers, representing all of life sciences, gathered in San Diego in late January to discuss the latest in automation and screening solutions. Improvements in automation and screening...
-
16:04WatchNeurodegenerative Diseases: Studying protein aggregation using NanoTemper instruments
Neurodegenerative diseases like Alzheimer’s or Parkinson’s Disease affect millions of people worldwide. Although current treatments may help relieve some of the physical or mental symptoms, there is s
-
ReadWhen aptamers are the better choice over mAbs
Monoclonal antibodies (mAbs) have become the molecule of choice when highly specific molecular recognition is needed for a variety of applications including disease diagnosis and therapy....
-
Read6 ingredients for a successful fragment library
Fragment-based drug discovery (FBDD) has become a major strategy to derive novel lead candidates in drug discovery. The principle of FBDD is to start with very small molecular fragments which may...
-
Read
4 ways to help you overcome the limitations of current methods in neurodegenerative disease research
-
ReadPROTACs: the game-changing technology that promises to tackle “undruggable” proteins
Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity. Unfortunately, there are still many target proteins — as much as 85% of the human...
-
Read5 things you must do while in Liverpool for ELRIG Drug Discovery
Here’s how to make your trip unforgettable. 1. Immerse yourself in Liverpool’s historic heart at the Royal Albert Dock This is the place to be for many iconic Liverpool attractions. Discover...
-
Read5 things you must do in Barcelona while at SLAS Europe (according to a local)
Here’s how to make your trip memorable. 1. Be awe-inspired at La Sagrada Familia There’s nothing like it anywhere in the world. Architecture, nature and spirituality come together to create...
-
ReadAnswering the demands for a new screening tool for drug discovery with Dianthus
There’s a gap that exists in screening tools for drug discovery — the need for fast, easy to use and flexible devices isn’t being satisfied. Enter Dianthus, introduced to come to the rescue. At...
-
ReadGreat things start small and so does the discovery of drug candidates
The famous painter Vincent Van Gogh once said, “Great things are done by a series of small things brought together.” This is exactly how drugs are developed by means of fragment-based screening —...
-
ReadNanoTemper Technologies Brings Speed to Drug Discovery Screening, Launches Dianthus System
PRESS RELEASE SOUTH SAN FRANCISCO, Calif. NanoTemper Technologies, maker of life science tools for protein characterization, launches its newest system, Dianthus, at the Society for Laboratory...
-
Loading more...
